| Randomized Study Drug . | Maribavir . | Valganciclovir . | P Value (Test) . |
|---|---|---|---|
| Received ≥21 d, n | 241 | 241 | |
| Days of study drug treatment, median (range) | 56 (21–62) | 55 (21–63) | |
| Primary end point achieved, n (%) | 187 (77.6) | 210 (87.1) | .008a |
| Recurrence of CMV DNA while on therapy, n (%) | 14 (5.8) | 0 | .0001a |
| Baseline plasma CMV DNA ≥9100 IU/mL, n | 42 | 44 | |
| Developed resistance mutation for study drug, n (%) | 24 (10) | 6 (2.5) | .001a |
| Days of study drug treatment, median (range) | 56 (40–60) | 55.5 (32–58) | |
| Days to detection of first DRM, median (range) | 56 (35–125) | 89.5 (66–110) | .007b |
| Recurrence of CMV DNA while on therapy, n (%) | 12 (50) | 0 | |
| Baseline plasma CMV DNA ≥9100 IU/mL, n (%) | 12 (50) | 3 (50) | |
| Primary end point achieved, n (%) | 4 (16.7) | 4 (66.7) | .03a |
| Randomized Study Drug . | Maribavir . | Valganciclovir . | P Value (Test) . |
|---|---|---|---|
| Received ≥21 d, n | 241 | 241 | |
| Days of study drug treatment, median (range) | 56 (21–62) | 55 (21–63) | |
| Primary end point achieved, n (%) | 187 (77.6) | 210 (87.1) | .008a |
| Recurrence of CMV DNA while on therapy, n (%) | 14 (5.8) | 0 | .0001a |
| Baseline plasma CMV DNA ≥9100 IU/mL, n | 42 | 44 | |
| Developed resistance mutation for study drug, n (%) | 24 (10) | 6 (2.5) | .001a |
| Days of study drug treatment, median (range) | 56 (40–60) | 55.5 (32–58) | |
| Days to detection of first DRM, median (range) | 56 (35–125) | 89.5 (66–110) | .007b |
| Recurrence of CMV DNA while on therapy, n (%) | 12 (50) | 0 | |
| Baseline plasma CMV DNA ≥9100 IU/mL, n (%) | 12 (50) | 3 (50) | |
| Primary end point achieved, n (%) | 4 (16.7) | 4 (66.7) | .03a |
Abbreviations: CMV, cytomegalovirus; d, days; DRM, drug resistance mutation.
aFisher exact test (2-tailed).
bStudent t test (2-tailed, unequal variances).
| Randomized Study Drug . | Maribavir . | Valganciclovir . | P Value (Test) . |
|---|---|---|---|
| Received ≥21 d, n | 241 | 241 | |
| Days of study drug treatment, median (range) | 56 (21–62) | 55 (21–63) | |
| Primary end point achieved, n (%) | 187 (77.6) | 210 (87.1) | .008a |
| Recurrence of CMV DNA while on therapy, n (%) | 14 (5.8) | 0 | .0001a |
| Baseline plasma CMV DNA ≥9100 IU/mL, n | 42 | 44 | |
| Developed resistance mutation for study drug, n (%) | 24 (10) | 6 (2.5) | .001a |
| Days of study drug treatment, median (range) | 56 (40–60) | 55.5 (32–58) | |
| Days to detection of first DRM, median (range) | 56 (35–125) | 89.5 (66–110) | .007b |
| Recurrence of CMV DNA while on therapy, n (%) | 12 (50) | 0 | |
| Baseline plasma CMV DNA ≥9100 IU/mL, n (%) | 12 (50) | 3 (50) | |
| Primary end point achieved, n (%) | 4 (16.7) | 4 (66.7) | .03a |
| Randomized Study Drug . | Maribavir . | Valganciclovir . | P Value (Test) . |
|---|---|---|---|
| Received ≥21 d, n | 241 | 241 | |
| Days of study drug treatment, median (range) | 56 (21–62) | 55 (21–63) | |
| Primary end point achieved, n (%) | 187 (77.6) | 210 (87.1) | .008a |
| Recurrence of CMV DNA while on therapy, n (%) | 14 (5.8) | 0 | .0001a |
| Baseline plasma CMV DNA ≥9100 IU/mL, n | 42 | 44 | |
| Developed resistance mutation for study drug, n (%) | 24 (10) | 6 (2.5) | .001a |
| Days of study drug treatment, median (range) | 56 (40–60) | 55.5 (32–58) | |
| Days to detection of first DRM, median (range) | 56 (35–125) | 89.5 (66–110) | .007b |
| Recurrence of CMV DNA while on therapy, n (%) | 12 (50) | 0 | |
| Baseline plasma CMV DNA ≥9100 IU/mL, n (%) | 12 (50) | 3 (50) | |
| Primary end point achieved, n (%) | 4 (16.7) | 4 (66.7) | .03a |
Abbreviations: CMV, cytomegalovirus; d, days; DRM, drug resistance mutation.
aFisher exact test (2-tailed).
bStudent t test (2-tailed, unequal variances).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
